Organization (Academic)
University of Buenos Aires
ClinicalTrials.gov lists University of Buenos Aires as lead sponsor of 10 trials. It has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Buenos Aires: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (32)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anxiety Disorders | 3 |
| Acute Coronary Syndrome | 2 |
| COVID-19 | 2 |
| Drug-Related Side Effects and Adverse Reactions | 2 |
| Obesity | 2 |
Showing 5 of 32 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 2 |
| 2019 | 2 |
| 2017 | 1 |
| 2012 | 2 |
| 2009 | 1 |
| 2008 | 1 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Alprazolam + Aerobic exercise | 1 |
| Fluoride | 1 |
| Levodopa + benserazide | 1 |
| (alprax) alprazolam | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 0 of 2 on time (n=2) |
Journals published in (52)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Lancet (London, England) | 3 |
| Trials | 3 |
| Aging | 2 |
| General hospital psychiatry | 2 |
| Journal of pain and symptom management | 2 |
Showing 5 of 52 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 11 | 7 | 2025-04-22 |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Ministerio de Ciencia, Tecnología e Innovación | Co sponsors trial with | 3 |
| Universidad Nacional Autónoma de México | Co sponsors trial with | 2 |
| Universidad Autónoma de Ciudad Juárez | Co sponsors trial with | 2 |
| Valencian International University | Co sponsors trial with | 2 |
| Pontificia Universidad Católica Argentina | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (31)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-04-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-07-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-04-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 31 events.
Biomarker capability evidence (7)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| COL7A1 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| FMR1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Biospecimen collected in a trial |
| GPT | Trial collaborator | Named in trial exclusion criteria |
| ALB | Trial collaborator | Mentioned in trial text |
Showing 5 of 7 evidence rows.
Biomarkers this organization publishes on (230)
Shown in this order: most publications first.
Showing 5 of 230 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.